ViiV impresses with Vocabria and Rekambys combo data

19 October 2023

The GSK (LSE: GSK) majority-owned company ViiV Healthcare is presenting 12-month efficacy, safety and patient-reported outcomes for European participants in the SOLAR study at the Annual European AIDS Conference (EACS) 2023 in Warsaw, Poland.

SOLAR is the first head-to-head study of the only complete long-acting HIV treatment regimen, Vocabria (cabotegravir injection) and Rekambys (rilpivirine injectable long-acting suspension) (CAB+RPV LA) compared to Biktarvy (bictegravir/emtricitabine/tenofovir [BIC/FTC/TAF]), a commonly prescribed daily oral HIV treatment.

Switching to CAB+RPV LA from BIC/FTC/TAF was shown to be well-tolerated and efficacious in maintaining virologic suppression among the European cohort, with strong preference for long-acting over daily oral therapy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK